EP1353671A4 - Neurotrophic tacrolimus analogs - Google Patents

Neurotrophic tacrolimus analogs

Info

Publication number
EP1353671A4
EP1353671A4 EP01991558A EP01991558A EP1353671A4 EP 1353671 A4 EP1353671 A4 EP 1353671A4 EP 01991558 A EP01991558 A EP 01991558A EP 01991558 A EP01991558 A EP 01991558A EP 1353671 A4 EP1353671 A4 EP 1353671A4
Authority
EP
European Patent Office
Prior art keywords
neurotrophic
tacrolimus analogs
tacrolimus
analogs
neurotrophic tacrolimus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01991558A
Other languages
German (de)
French (fr)
Other versions
EP1353671A1 (en
Inventor
Nobuya Matsuoka
Takayuki Yamaji
Bruce Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of EP1353671A1 publication Critical patent/EP1353671A1/en
Publication of EP1353671A4 publication Critical patent/EP1353671A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP01991558A 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs Withdrawn EP1353671A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29
US258500P 2000-12-29
PCT/US2001/050419 WO2002053159A1 (en) 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs

Publications (2)

Publication Number Publication Date
EP1353671A1 EP1353671A1 (en) 2003-10-22
EP1353671A4 true EP1353671A4 (en) 2004-07-14

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01991558A Withdrawn EP1353671A4 (en) 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs

Country Status (18)

Country Link
EP (1) EP1353671A4 (en)
JP (1) JP2004527472A (en)
KR (2) KR20070030331A (en)
CN (1) CN1293877C (en)
AR (1) AR035411A1 (en)
AU (1) AU2002231277B2 (en)
BR (1) BR0116762A (en)
CA (1) CA2433384A1 (en)
CZ (1) CZ20032060A3 (en)
HU (1) HUP0302521A3 (en)
IL (1) IL156664A0 (en)
MX (1) MXPA03005941A (en)
NO (1) NO20032913D0 (en)
NZ (1) NZ527209A (en)
PL (1) PL366301A1 (en)
RU (1) RU2288716C2 (en)
WO (1) WO2002053159A1 (en)
ZA (1) ZA200305806B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
CA2554045A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
JP2009102226A (en) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd Therapeutic agent for spinal cord injury
JP5878015B2 (en) * 2008-07-23 2016-03-08 ノバルティス アーゲー Sphingosine monophosphate receptor modulators and their use to treat muscle inflammation
JP2015511242A (en) * 2012-02-23 2015-04-16 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル） Calcineurin inhibitors for use in the treatment of pathological vestibular disorders
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323042A1 (en) * 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
WO1993014771A1 (en) * 1992-02-01 1993-08-05 Fisons Plc Macrocyclic compounds in the prophylactic treatment of aids
WO1994004148A1 (en) * 1992-08-25 1994-03-03 Fisons Plc Use of macrolide compounds for the treatment of reversible obstructive airways disease
WO2001005385A2 (en) * 1999-07-21 2001-01-25 Fujisawa Pharmaceutical Co Ltd New use of a macrolide compound for treating neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001225B (en) * 1989-09-14 1993-06-30 Fisons Plc Novel macrocyclic compositions and new application method thereof
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323042A1 (en) * 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
WO1993014771A1 (en) * 1992-02-01 1993-08-05 Fisons Plc Macrocyclic compounds in the prophylactic treatment of aids
WO1994004148A1 (en) * 1992-08-25 1994-03-03 Fisons Plc Use of macrolide compounds for the treatment of reversible obstructive airways disease
WO2001005385A2 (en) * 1999-07-21 2001-01-25 Fujisawa Pharmaceutical Co Ltd New use of a macrolide compound for treating neurodegenerative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOLD B G: "NEUROIMMUNOPHILIN LIGANDS: EVALUATION OF THEIR THERAPEUTIC POTENTIAL FOR THE TREATMENT OF NEUROLOGICAL DISORDERS", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 9, no. 10, 2000, pages 2331 - 2342, XP001011856, ISSN: 1354-3784 *
See also references of WO02053159A1 *
STEINER ET AL: "Neurotrophic actions of non-immunosuppressive analogs of immunosuppressive drugs FK506, rapamycin and cyclosporin A", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 4, April 1997 (1997-04-01), pages 421 - 428, XP002125244, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
AU2002231277B2 (en) 2006-11-30
IL156664A0 (en) 2004-01-04
ZA200305806B (en) 2005-01-26
CN1538843A (en) 2004-10-20
HUP0302521A2 (en) 2003-11-28
KR20040007431A (en) 2004-01-24
CA2433384A1 (en) 2002-07-11
EP1353671A1 (en) 2003-10-22
JP2004527472A (en) 2004-09-09
MXPA03005941A (en) 2005-02-14
NO20032913D0 (en) 2003-06-24
NZ527209A (en) 2005-09-30
PL366301A1 (en) 2005-01-24
KR100794204B1 (en) 2008-01-14
WO2002053159A1 (en) 2002-07-11
AR035411A1 (en) 2004-05-26
CZ20032060A3 (en) 2004-01-14
CN1293877C (en) 2007-01-10
BR0116762A (en) 2004-08-10
RU2288716C2 (en) 2006-12-10
HUP0302521A3 (en) 2007-03-28
KR20070030331A (en) 2007-03-15
RU2003123493A (en) 2005-01-20

Similar Documents

Publication Publication Date Title
AU4114201A (en) Cyclic compounds
CZ20011732A3 (en) Elevator
SG99909A1 (en) Elevator
AU145133S (en) Rack
AU2002360487A8 (en) Acyclovir-peptide analogs
TW478635U (en) Building-block-assembled-type rack
EG23909A (en) Vatamin d, analogs
IL158486A (en) Nociceptin analogs
AU146998S (en) Rack
EP1353671A4 (en) Neurotrophic tacrolimus analogs
GB0022877D0 (en) Analogues
AU146997S (en) Rack
GB0006193D0 (en) Platforms
AU9174501A (en) Novel mitogen activated kinase
TW428699U (en) Lampstand structure
SI1414828T1 (en) Antitumoral analogs
TW561883U (en) Structure for changing exercises
AU141364S (en) Rack
TW444796U (en) Bump-resistant structure for aid-lock
TW485996U (en) Multiple-functional movable floor structure
GB0006388D0 (en) Promoter
TW459910U (en) Combination structure for door-in-door
GB0005151D0 (en) None
AU142390S (en) Roof rack foot assembly
GB0016622D0 (en) Integral inflated groundsheet

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040528

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/28 B

Ipc: 7A 61P 25/00 B

Ipc: 7A 61K 31/436 A

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1059891

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTELLAS PHARMA INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091121

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1059891

Country of ref document: HK